PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Clin Immunol. Author manuscript; available in PMC 2010 October 5.
Published in final edited form as:
PMCID: PMC2949956
NIHMSID: NIHMS236616

The role of X-linked FOXP3 in the autoimmune susceptibility of Turner Syndrome patients

Abstract

Turner Syndrome patients have an absent second sex chromosome and a predisposition to autoimmune disease. We hypothesized that the autoimmune susceptibility in Turner Syndrome may be due to an alteration in the expression of the X-linked FOXP3 gene. FOXP3 is important in the development of regulatory T cells, and complete loss of FOXP3 expression has been shown to result in severe autoimmunity. To test this hypothesis, we characterized the regulatory T cells and performed immunophenotyping on the peripheral blood leukocytes of a cohort of Turner Syndrome patients. These patients retained regulatory T cell frequency and function despite an increased prevalence of autoimmunity. Immunophenotyping revealed a decrease in the ratio of CD4 to CD8 lymphocytes. These findings suggest that the autoimmune predisposition in Turner Syndrome is not due to alterations in regulatory T cells but may be associated with a change in the proportion of T cell subsets.

Keywords: Turner Syndrome, FOXP3, Regulatory T cells, Autoimmunity

Introduction

Turner Syndrome (TS) patients have an absent second sex chromosome and a number of physical findings including short stature and absent pubertal development [1]. Interestingly, TS patients also have an increased incidence of autoimmune disease [1]. Hashimoto thyroiditis is the most common autoimmune disease with a prevalence of approximately 20% in TS patients [2]. Other reported autoimmune diseases include Graves' hyperthyroidism [3], alopecia [1], inflammatory bowel disease [4], and psoriasis [1]. Why TS patients are predisposed to autoimmune disease, however, is not known.

Some of the clinical findings associated with TS are believed to be due to an altered dosage of certain X chromosome genes [1]. Short stature in TS, for example, has been attributed to decreased expression of the X-linked SHOX gene in TS [5]. We therefore asked whether the predisposition to autoimmunity seen in TS could be due to altered dosage of an X-linked gene, FOXP3.

FOXP3 is a transcription factor that is important for the development and maintenance of regulatory T cells (Tregs) (reviewed in [6]). Tregs are a CD4+ T cell lymphocyte subset that plays a key role in preventing autoimmunity. Humans and mice with mutations in FOXP3 lack Tregs and develop severe lymphoproliferation and autoimmunity [7]. Quantitative decreases in FOXP3 expression in mice have also been shown to alter Treg function and result in autoimmune disease [8]. Notably, the thyroid autoimmunity in TS has been mapped to Xp11.2–p22.1 [9], a chromosomal region containing the FOXP3 gene.

To investigate whether the increased incidence of autoimmune diseases seen in TS may be due to quantitative changes in the Tcell subset expressing FOXP3 expression, we examined Tregs in the peripheral blood of a cohort of TS patients. We found that TS patients do not have an alteration in the frequency of Tregs and retain the ability to suppress effector T cell function. TS patients, however, did have a decrease in the CD4 to CD8 lymphocyte ratio in the peripheral blood, suggesting an immune alteration that may be associated with autoimmunity.

Materials and methods

Participants

A total of 30 participants (20 TS patients and 10 controls) were recruited through the University of California, San Francisco (UCSF) Endocrinology Clinics. The diagnosis of TS was verified by medical chart review. Blood samples were obtained with informed consent and/or assent under an Institutional Review Board approved protocol at UCSF.

Peripheral blood mononuclear cell (PBMC) isolation

PBMCs were isolated at the UCSF Pediatric Clinical Resarch Center using Ficoll–Hypaque. Whole blood was diluted in PBS at a 1:1 ratio and overlayed onto an equivalent volume of Ficoll–Hypaque. The gradient was centrifuged at 400×g for 30 min and PBMCs removed. The PBMCs were then washed twice with PBS, counted and cryopreserved.

Antibodies

Antibodies used for staining (PERCP-conjugated anti CD4, APC-conjugated anti CD25, PE-conjugated anti CD127, PECy-conjugated anti CD8, PERCP-conjugated anti CD19, FITC-conjugated anti CD14, and PE-conjugated anti CD45) and sorting (FITC-conjugated anti CD4, APC-conjugated anti CD25, and PE-conjugated anti CD127) were provided by Becton Dickinson (BD Biosciences). Alexa 488-conjugated anti FOXP3 (Clone 206D) was purchased from Biolegend.

Flow cytometry

Frozen PBMCs were removed from liquid nitrogen and warmed to 37 °C. Cells were washed twice in 10% fetal calf serum in Dulbecco's Modified Eagle's Medium and counted. FOXP3 intracellular staining was performed according to manufacturer's instructions (Biolegend). For quantitation of immune cell subsets, 10 µl of pre-mixed panels of antibodies were used per 106 cells. Flow cytometry was performed using the LSR II Flow Cytometer (BD Biosciences).

Sorting of Tregs

Sorting of Tregs was performed as previously described [10]. In brief, frozen PBMCs were removed from liquid nitrogen and warmed to 37 °C. Cells were washed twice in PBS, counted and resuspended at a concentration of 100×106 per ml for cell staining. Tregs (CD4+, CD127lo/−, CD25+) cells were sorted using a Moflo cell sorter (Beckman Coulter) into 50% human serum.

Suppression assays

Suppression assays were performed using 30,000 sorted Tregs and 100,000 allogeneic PBMCs as responders in round-bottom 96 well plates. Antigen presenting cells were allogeneic PBMCs irradiated with 40 Gy. Antigen presenting cells were plated at a concentration of 100,000 cells/well. Total volume per well was 200 µl. Anti-CD3 and anti-CD28 were added to the wells at final concentration of 1 µg/ml. On day 4, 1 µCi of 3H-thymidine was added for the final 16 h. Plates were harvested using a Tomtec cell harvester and 3H-thymidine incorporation was determined using a 1450 microbeta Wallac Trilux liquid scintillation counter. Percent suppression was calculated as [1−(cpm co-cultures/cpm co-cultures of responders alone)]×100.

Statistics

Results were analyzed by Mann–Whitney test using Prism 4 software (GraphPad). p values <0.05 were considered significant.

Results

Turner Syndrome patients have a high prevalence of autoimmune disease

We collected a cohort of 20 TS and 10 control patients and obtained medical histories from the patients and from available medical charts (Table 1). Ages ranged from 8 to 62 years in TS patients and 7 to 62 years in control patients. Mean ages were not significantly different between TS (22.8±13.1 years) and control (30.4±19.7 years) patients. Similar to previous reports [1], a high prevalence (40%) of autoimmune disease was seen in TS patients. 3 of the 20 (15%) TS patients had clinically significant thyroid disease, and 1 additional TS patient had detectable thyroid autoantibodies (Table 1). A variety of other autoimmune diseases, including psoriasis, idiopathic thrombocytopenic purpura (ITP), and Crohn's Disease, was also seen in our cohort (Table 1).

Table 1
Patient demographics

The frequency and suppressive function of regulatory T cells is not altered in Turner Syndrome

We utilized flow cytometry to determine whether the percentage of Treg subsets (defined as the percentage of FOXP3+ cells within CD4+ lymphocytes) was decreased in TS patients as a possible cause of increased autoimmunity. FOXP3+ cells were easily detected in the peripheral blood of both TS and control patients (Fig. 1A). The average percentage of FOXP3+ in the CD4+ gate was not significantly different between the cohort of TS (4.03% ±1.43) and control (4.62%±1.53) patients (Fig. 1B). Furthermore, the subgroup of TS patients with known autoimmune disease showed no difference in the percentage of Tregs (4.34%±1.22) when compared with controls (4.62%±1.53) (Fig. 1B, right).

Figure 1
TS Patients Retain Treg Frequency and Suppressive Function. (A) Representative flow cytometric plots of PBMCs from a TS patient (upper panels) and a control patient (bottom panels). The percentage of FOXP3+ cells within CD4+ gated lymphocytes (left) and ...

We next determined whether the suppressive function of Tregs in TS patients might be altered. To do this, we performed allogeneic responder cell suppression assays with a polyclonal stimulus using sorted Tregs and responders at decreasing ratios. Tregs were sorted based on the cell surface markers CD4+, CD127lo/−, CD25+ as has previously been described [10]. We have previously shown that this sorting scheme results in a Treg population that is typically greater than 94% FOXP3+ [10]. As shown in Fig. 1C, Tregs from TS patients were able to suppress effector T cell proliferation at comparable levels to those in control patients. At a 1:2 ratio of Tregs to responders, the average percent suppression was 36.9%±6.5% in Turners patients and 42.3%±8.8% in control subjects (p=0.34).

Turner Syndrome patients have a decreased CD4 to CD8 ratio in peripheral blood

Previous studies have yielded conflicting reports on how the cellular immunophenotype of TS patients may differ from controls [1114]. Interestingly, two studies have reported a decrease in the CD4 to CD8 lymphocyte ratio in the peripheral blood of TS patients [12,14]. Consistent with these two previous reports, we also found that TS patients have a decreased CD4 to CD8 ratio compared with controls (p=0.02, Figs. 2A and B). While the average percent of CD4+ T cells in the lymphocyte population was not significantly different between TS patients and controls (Fig. 2C), the average percent of CD8+ T cells was higher in TS patients than in controls (p=0.04, Fig. 2D). We did not find any significant differences in the frequency of B cells (Fig. 2E), macrophages (Fig. 2F), or NK cells (Fig. 2G) in TS patients compared with controls.

Figure 2
TS Patients Have a Decreased CD4 to CD8 Ratio in the Peripheral Blood. (A) Representative flow cytometric plots of PBMCs showing percentage of CD4+ and CD8+ cells within lymphocytes in a TS (left) and control (right) subject. (B) Ratio of the percent ...

Discussion

In this study, we show that the frequency and suppressive function of Tregs in TS patients do not appear to be altered despite an increased predisposition to autoimmunity. The role of Tregs in the pathogenesis of autoimmune diseases has been the subject of intensive investigation in recent years (reviewed in [15]). While loss of Tregs due to FOXP3 mutations has been well-linked to the Immunodysregulation Polyendocrinopathy Enteropathy X-linked (IPEX) syndrome [16], the connection between more subtle changes in Tregs and other autoimmune diseases are less clear. For example, whether alterations in Treg number and function contribute to the pathogenesis of Type I Diabetes Mellitus (T1DM) has been controversial [17,18].

A limitation of our study is the heterogeneity of our study group. Our cohort consisted of TS patients with a number of different karyotypes (Table 1) and with a large spread in ages, which may obscure any differences that may exist. Indeed, there is evidence that the frequency of Tregs may be largely dependent on age [17].

TS patients may be predisposed to autoimmunity for other reasons besides Treg alterations. First, aneuploidy itself may predispose to autoimmunity. A number of aneuploid conditions, including Down Syndrome (Trisomy 21) and Klinefelter's Syndrome (XXY), have also been associated with increased risk of autoimmunity [1]. Second, other genes on the X chromosome may be playing a role in the predisposition to autoimmunity in TS. A number of immune-related genes, including those involved in Wiskott–Aldrich Syndrome and Bruton's Agammaglobulinemia, are linked to the X chromosome [19]. Third, TS patients may have a defect in thymic negative selection of self-reactive T cells. Recent studies have highlighted the importance of this mechanism in the maintenance of self-tolerance in a number of diseases, including Autoimmune Polyendocrinopathy Syndrome Type 1 [20,21], Type 1 Diabetes Mellitus [22], and Myasthenia Gravis [23].

Consistent with two previous reports [12,14], we have also noted a decrease in the CD4 to CD8 ratio in our Turner Syndrome cohort. This derangement in the immune phenotype of Turner patients may be related to the increased autoimmunity. Further studies will have to be performed to understand the significance of this finding.

Acknowledgments

We thank subjects and their families for their participation in this study. Samples were processed at the UCSF Pediatric Clinical Research Center. We thank members of the Bluestone and Anderson labs for critical review of this manuscript. M.S.A. is supported by the Pew Scholars Program, Sandler Foundation, and the Burroughs Wellcome Fund. This project was supported by NIH/NCRR UCSF-CTSI Grant Number UL1 RR024131. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.

References

1. Sperling M. Pediatric endocrinology. Philadelphia: Saunders; 2008.
2. Livadas S, Xekouki P, Fouka F, Kanaka-Gantenbein C, Kaloumenou I, Mavrou A, Constantinidou N, Dacou-Voutetakis C. Prevalence of thyroid dysfunction in Turner's syndrome: a long-term follow-up study and brief literature review. Thyroid. 2005;15:1061–1066. [PubMed]
3. Brooks WH, Meek JC, Schimke RN. Gonadal dysgenesis with Graves's disease. J. Med. Genet. 1977;14:128–129. [PMC free article] [PubMed]
4. Hayward PA, Satsangi J, Jewell DP. Inflammatory bowel disease and the X chromosome. 1996:713–718. [PubMed]
5. Rao E, Weiss B, Fukami M, Rump A, Niesler B, Mertz A, Muroya K, Binder G, Kirsch S, Winkelmann M, Nordsiek G, Heinrich U, Breuning MH, Ranke MB, Rosenthal A, Ogata T, Rappold GA. Pseudoautosomal deletions encompassing a novel homeobox gene cause growth failure in idiopathic short stature and Turner Syndrome. Nat. Genet. 1997;16:54–63. [PubMed]
6. Tang Q, Bluestone JA. The Foxp3+ regulatory Tcell: a jack of all trades, master of regulation. Nat. Immunol. 2008;9:239–244. [PMC free article] [PubMed]
7. Wildin RS, Ramsdell F, Peake J, Faravelli F, Casanova JL, Buist N, Levy-Lahad E, Mazzella M, Goulet O, Perroni L, Bricarelli FD, Byrne G, McEuen M, Proll S, Appleby M, Brunkow ME. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat. Genet. 2001;27:18–20. [PubMed]
8. Salomon B, Lenschow DJ, Rhee L, Ashourian N, Singh B, Sharpe A, Bluestone JA. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity. 2000;12:431–440. [PubMed]
9. Zinn AR, Tonk VS, Chen Z, Flejter WL, Gardner HA, Guerra R, Kushner H, Schwartz S, Sybert VP, Van Dyke DL, Ross JL. Evidence for a Turner Syndrome locus or loci at Xp11.2–p22.1. Am. J. Hum. Genet. 1998;63:1757–1766. [PubMed]
10. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, Gottlieb PA, Kapranov P, Gingeras TR, Fazekas de St Groth B, Clayberger C, Soper DM, Ziegler SF, Bluestone JA. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J. Exp. Med. 2006;203:1701–1711. [PMC free article] [PubMed]
11. Lorini R, Ugazio AG, Cammareri V, Larizza D, Castellazzi AM, Brugo MA, Severi F. Immunoglobulin levels, T-cell markers, mitogen responsiveness and thymic hormone activity in Turner's Syndrome. Thymus. 1983;5:61–66. [PubMed]
12. Stenberg AE, Sylven L, Magnusson CG, Hultcrantz M. Immunological parameters in girls with Turner Syndrome. J. Negat. Results. Biomed. 2004;3:6. [PMC free article] [PubMed]
13. Cacciari E, Masi M, Fantini MP, Licastro F, Cicognani A, Pirazzoli P, Villa MP, Specchia F, Forabosco A, Franceschi C, Martoni L. Serum immunoglobulins and lymphocyte subpopulations derangement in Turner's Syndrome. J. Immunogenet. 1981;8:337–344. [PubMed]
14. Rongen-Westerlaken C, Rijkers GT, Scholtens EJ, van Es A, Wit JM, van den Brande JL, Zegers BJ. Immunologic studies in Turner Syndrome before and during treatment with growth hormone. The Dutch Growth Hormone Working Group. J. Pediatr. 1991;119:268–272. [PubMed]
15. Valencia X, Lipsky PE. CD4+CD25+FoxP3+ regulatory T cells in autoimmune diseases. Nat. Clin. Pract. Rheumatol. 2007;3:619–626. [PubMed]
16. Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L, Kelly TE, Saulsbury FT, Chance PF, Ochs HD. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat. Genet. 2001;27:20–21. [PubMed]
17. Brusko T, Wasserfall C, McGrail K, Schatz R, Viener HL, Schatz D, Haller M, Rockell J, Gottlieb P, Clare-Salzler M, Atkinson M. No alterations in the frequency of FOXP3+ regulatory T-cells in type 1 diabetes. Diabetes. 2007;56:604–612. [PubMed]
18. Kriegel MA, Lohmann T, Gabler C, Blank N, Kalden JR, Lorenz HM. Defective suppressor function of human CD4+ CD25+ regulatory T cells in autoimmune polyglandular syndrome type II. J. Exp. Med. 2004;199:1285–1291. [PMC free article] [PubMed]
19. Hernandez-Molina G, Svyryd Y, Sanchez-Guerrero J, Mutchinick OM. The role of the X chromosome in immunity and autoimmunity. Autoimmun. Rev. 2007;6:218–222. [PubMed]
20. Anderson MS, Venanzi ES, Chen Z, Berzins SP, Benoist C, Mathis D. The cellular mechanism of aire control of T cell tolerance. Immunity. 2005;23:227–239. [PubMed]
21. Anderson MS, Venanzi ES, Klein L, Chen Z, Berzins SP, Turley SJ, von Boehmer H, Bronson R, Dierich A, Benoist C, Mathis D. Projection of an immunological self shadow within the thymus by the aire protein. Science. 2002;298:1395–1401. [PubMed]
22. Pugliese A, Zeller M, Fernandez A, Jr, Zalcberg LJ, Bartlett RJ, Ricordi C, Pietropaolo M, Eisenbarth GS, Bennett ST, Patel DD. The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR–IDDM2 susceptibility locus for type 1 diabetes. Nat. Genet. 1997;15:293–297. [PubMed]
23. Giraud M, Taubert R, Vandiedonck C, Ke X, Levi-Strauss M, Pagani F, Baralle FE, Eymard B, Tranchant C, Gajdos P, Vincent A, Willcox N, Beeson D, Kyewski B, Garchon HJ. An IRF8-binding promoter variant and AIRE control CHRNA1 promiscuous expression in thymus. Nature. 2007;448:934–937. [PubMed]
24. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol. 2003;4:330–336. [PubMed]